DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ACETIC ACID
» See Plans and Pricing
All Clinical Trials for Acetic Acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003697 | Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors | Completed | University of Glasgow | Phase 1 | 1995-10-01 | RATIONALE: Dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors that have not responded to previous therapy. |
| NCT00044213 | Trial to Assess Chelation Therapy (TACT) | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00044213 | Trial to Assess Chelation Therapy (TACT) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00044213 | Trial to Assess Chelation Therapy (TACT) | Completed | Mt. Sinai Medical Center, Miami | Phase 3 | 2003-09-01 | The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. |
| NCT00051545 | Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | Terminated | LEO Pharma | Phase 3 | 1999-11-01 | To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC). |
| NCT00116454 | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis | Completed | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 3 | 2005-07-01 | The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation. |
| NCT00282061 | Synchronization and Desynchronization Between Circadian Rhythms in Patients With Delayed Sleep Phase Syndrome (DSPS) | Unknown status | Sheba Medical Center | Phase 1 | 1969-12-31 | This study's first aim is to widen the knowledge of the characteristics of delayed sleep phase disorder (DSPS) by focusing on the circadian rhythms of appetite regulation factors and their phase relations to the cycles of sleep-wake, melatonin, cortisol and body temperature. This study's second aim is to assess the influence of forced morning awakening, as a daily struggle faced by DSPS patients, upon the synchronization of these variables in DSPS patients. The investigators hypothesize that the chronic incompatibility between the endogenous sleep-wake rhythm of the DSPS patients and the morning wakefulness, as a social demand, may impair the synchronization between the different rhythms, as findings indicate in normal subjects under jet lag. And finally, the third aim of the study is to assess the influence of successful treatment with melatonin upon the phase locations of circadian rhythms of studied measures and the synchronization between them. These measures will be assessed in a controlled study, for 36 hours (sampled every 2 hours) under three distinct experimental conditions: first, under free sleep-wake conditions (ad-libitum bedtime and arousal); second, under restricted sleep-wake conditions (enforced morning wake-up); and finally, after 12 weeks of melatonin treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Acetic Acid
Condition Name
Clinical Trial Locations for Acetic Acid
Trials by Country
Clinical Trial Progress for Acetic Acid
Clinical Trial Phase
Clinical Trial Sponsors for Acetic Acid
Sponsor Name
